Chemical Property of Purvalanol B
Chemical Property:
- Vapor Pressure:2.37E-18mmHg at 25°C
- Melting Point:58.5 °C
- Boiling Point:660.6°Cat760mmHg
- PKA:2.81±0.25(Predicted)
- Flash Point:353.3°C
- PSA：125.19000
- Density:1.43g/cm3
- LogP:4.07720
- Storage Temp.:−20°C
- Solubility.:DMSO: 37 mg/mL, soluble
- XLogP3:3.8
- Hydrogen Bond Donor Count:4
- Hydrogen Bond Acceptor Count:8
- Rotatable Bond Count:8
- Exact Mass:432.1676664
- Heavy Atom Count:30
- Complexity:583
- Purity/Quality:
-
97% *data from raw suppliers
Purvalanol B ≥95% *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Total 1 MSDS from other Authors
Useful:
- Canonical SMILES:CC(C)C(CO)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NC3=CC(=C(C=C3)C(=O)O)Cl
- Isomeric SMILES:CC(C)[C@H](CO)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NC3=CC(=C(C=C3)C(=O)O)Cl
-
Description
Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. Purvalanol B is a CDK inhibitor that most potently inhibits Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p35, and Cdk2/cyclin B (IC50s = 6, 9, 6, and 6 nM, respectively). It is inactive against Cdk4/cyclin D1 as well as several other protein kinases. Purvalanol B is a 2,6,9-trisubstituted purine that, at micromolar doses, inhibits the growth of parasites, including Plasmodium.
-
Uses
Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. Purvalanol B is a CDK inhibitor that most potently inhibits Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p35, and Cdk2/cyclin B (IC50s = 6, 9, 6, and 6 nM, respectively). It is inactive against Cdk4/cyclin D1 as well as several other protein kinases. Purvalanol B is a 2,6,9-trisubstituted purine that, at micromolar doses, inhibits the growth of parasites, including Plasmodium. Purvalanol B is a potent cyclin-dependent kinase 2 (CDK2) inhibitor. These cyclin-dependent kinases play key roles in the regulation of the cell cycle and small molecules that inhibit these proteins have therapeutic potential against various proliferative and neurodegenerative disorders.
